Oncogenic EGFR rewires STING-TBK1 immune machinery to license DNA damage tolerance
Qin Shen, Mei Chen, Yidan Chen, Qian Zhang, Qingzhe Wu, Xinyuan Yu, Fei Zhang, Shengduo Liu, Chen Chen, Cunqi Ye, Qi Zhang, Xin‐Hua Feng, Hai Xin Song, Tingbo Liang, Penghong Song, , Pinglong Xu
This study reveals that oncogenic EGFR mutations exploit the STING-TBK1 immune pathway to enhance DNA damage repair and therapeutic resistance in NSCLC.
bioRxiv · Oct 20, 2025 · PreprintCancer Biology